Future trials should, thus, focus on the role of HDAC-2 in triple negative breast cancer, by explicitly using or, at least, distinguishing triple negative breast cancer samples from other breast cancer subtypes that evidently exhibit distinctive molecular patterns. The gene discussed is HDAC2; the disease is breast cancer.